Tango Therapeutics (TNGX) EBIAT (2020 - 2025)
Historic EBIAT for Tango Therapeutics (TNGX) over the last 6 years, with Q3 2025 value amounting to $15.9 million.
- Tango Therapeutics' EBIAT rose 15445.88% to $15.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$100.5 million, marking a year-over-year increase of 1854.21%. This contributed to the annual value of -$130.3 million for FY2024, which is 2806.85% down from last year.
- Latest data reveals that Tango Therapeutics reported EBIAT of $15.9 million as of Q3 2025, which was up 15445.88% from -$38.9 million recorded in Q2 2025.
- Tango Therapeutics' EBIAT's 5-year high stood at $15.9 million during Q3 2025, with a 5-year trough of -$39.9 million in Q1 2025.
- In the last 5 years, Tango Therapeutics' EBIAT had a median value of -$25.6 million in 2024 and averaged -$24.3 million.
- As far as peak fluctuations go, Tango Therapeutics' EBIAT crashed by 95180677.97% in 2021, and later soared by 15445.88% in 2025.
- Over the past 5 years, Tango Therapeutics' EBIAT (Quarter) stood at -$22.0 million in 2021, then crashed by 31.82% to -$29.1 million in 2022, then dropped by 5.86% to -$30.8 million in 2023, then dropped by 22.45% to -$37.7 million in 2024, then soared by 142.17% to $15.9 million in 2025.
- Its EBIAT was $15.9 million in Q3 2025, compared to -$38.9 million in Q2 2025 and -$39.9 million in Q1 2025.